USA - engelsk - NLM (National Library of Medicine)

ranbaxy pharmaceuticals inc. - oxycodone hydrochloride (unii: c1enj2te6c) (oxycodone - unii:cd35pmg570) - oxycodone hydrochloride 40 mg - oxycodone hcl extended-release tablets is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. limitations of use oxycodone hcl extended-release tablets is contraindicated in patients with: clinical considerations fetal/neonatal adverse reactions prolonged use of opioid analgesics during pregnancy for medical or nonmedical purposes can result in physical dependence in the neonate and neonatal opioid withdrawal syndrome shortly after birth. observe newborns for symptoms of neonatal opioid withdrawal syndrome, such as poor feeding, diarrhea, irritability, tremor, rigidity, and seizures, and manage accordingly [see warnings and precautions (5.3)] . teratogenic effects - pregnancy category c there are no adequate and well-controlled studies in pregnant women. oxycodone hcl extended-release tablets should be used during pregnancy only if the potential benefit justifies the risk to the fetus.

USA - engelsk - NLM (National Library of Medicine)

ethex corporation - oxycodone hydrochloride (unii: c1enj2te6c) (oxycodone - unii:cd35pmg570) - oxycodone hydrochloride 10 mg - oxycodone hcl controlled-release tablets are a controlled-release oral formulation of oxycodone hydrochloride indicated for the management of moderate to severe pain when a continuous, around-the-clock analgesic is needed for an extended period of time. oxycodone hcl controlled-release tablets are not intended for use as a prn analgesic. physicians should individualize treatment in every case, initiating therapy at the appropriate point along a progression from non-opioid analgesics, such as non-steroidal anti-inflammatory drugs and acetaminophen to opioids in a plan of pain management such as outlined by the world health organization, the agency for healthcare research and quality (formerly known as the agency for health care policy and research), the federation of state medical boards model guidelines, or the american pain society. oxycodone hcl controlled-release tablets are not indicated for pain in the immediate postoperative period (the first 12-24 hours following surgery), or if the pain is mild, or n

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - oxycodone hydrochloride, quantity: 50 mg - injection, solution - excipient ingredients: citric acid monohydrate; sodium citrate dihydrate; sodium chloride; hydrochloric acid; sodium hydroxide; water for injections - the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated, or are otherwise inappropriate to provide sufficient management of pain.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - oxycodone hydrochloride, quantity: 200 mg - injection, solution - excipient ingredients: citric acid monohydrate; sodium citrate dihydrate; sodium chloride; hydrochloric acid; sodium hydroxide; water for injections - the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated, or are otherwise inappropriate to provide sufficient management of pain.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - oxycodone hydrochloride, quantity: 20 mg - injection, solution - excipient ingredients: citric acid monohydrate; sodium citrate dihydrate; sodium chloride; hydrochloric acid; sodium hydroxide; water for injections - the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated, or are otherwise inappropriate to provide sufficient management of pain.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - oxycodone hydrochloride, quantity: 10 mg - injection, solution - excipient ingredients: citric acid monohydrate; sodium citrate dihydrate; sodium chloride; hydrochloric acid; sodium hydroxide; water for injections - the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated, or are otherwise inappropriate to provide sufficient management of pain.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

boucher & muir pty ltd - oxycodone hydrochloride, quantity: 5 mg - capsule, hard - excipient ingredients: gelatin; microcrystalline cellulose; iron oxide red; sodium laureth sulfate; titanium dioxide; indigo carmine; iron oxide yellow; magnesium stearate - oxycodone bnm is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

boucher & muir pty ltd - oxycodone hydrochloride, quantity: 20 mg - capsule, hard - excipient ingredients: iron oxide red; magnesium stearate; microcrystalline cellulose; titanium dioxide; indigo carmine; gelatin; sodium laureth sulfate; iron oxide yellow - oxycodone bnm is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

boucher & muir pty ltd - oxycodone hydrochloride, quantity: 10 mg - capsule, hard - excipient ingredients: gelatin; iron oxide red; titanium dioxide; microcrystalline cellulose; indigo carmine; magnesium stearate; iron oxide yellow; sodium laureth sulfate - oxycodone bnm is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

USA - engelsk - NLM (National Library of Medicine)

mckesson corporation - oxycodone hydrochloride (unii: c1enj2te6c) (oxycodone - unii:cd35pmg570) - oxycodone hydrochloride 5 mg - oxycodone hydrochloride (hcl) tablets are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. limitations of use because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see warnings and precautions (5.1)], reserve oxycodone hcl tablets for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or opioid combination products): - have not been tolerated or are not expected to be tolerated, - have not provided adequate analgesia or are not expected to provide adequate analgesia. oxycodone hcl is contraindicated in patients with: - significant respiratory depression [see warnings and precautions (5.2)] - acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment or hypercarbia [see warnings and precautions (5.6)] - known or suspected gastrointestinal obstruction, including paralytic ileus [see warnings and precautions (5